Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANI Pharmaceuticals Inc.

www.anipharmaceuticals.com

Latest From ANI Pharmaceuticals Inc.

Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway

Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.

Deals M & A

ANI Grabs 23 US Products From Amerigen

In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.

Deals United States

The Factory Floor: Aurobindo Receives Another Form 483

Aurobindo has received further Form 483s from the FDA, while Biocon has received an EIR for its Bengaluru facility. The FDA has also successfully concluded inspections for Indoco and Lupin, while ANI, Aptar and MicroSphere have made strategic moves.

Manufacturing Compliance

Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.

Clinical Trials Research and Development Strategies
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Generic Drugs
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • ANIP Acquisition Co.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ANI Pharmaceuticals Inc.
  • Senior Management
  • Arthur S Przybyl, Pres. & CEO
    Stephen P Carey, VP, CFO
    Robert W Schrepfer, SVP, Bus. Dev. & Spec. Sales
  • Contact Info
  • ANI Pharmaceuticals Inc.
    Phone: (218) 634-3500
    210 Main St. W.
    Baudette, MN 56623
    USA
UsernamePublicRestriction

Register